bold-100
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
1
Phase 4
0
Earliest trial started Dec 3, 2018 (NCT04319575)
Timeline
Indications
Mechanism of action
- 78 kDa glucose-regulated proteinINHIBITOR
HSPA5 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07027423 | Phase 1 | Jun 30, 2025 | University of Toronto |
| NCT04421820 | Phase 1 | Aug 15, 2020 | Bold Therapeutics, Inc. |
| NCT04319575 | Phase 2/Phase 3 (Phase 3) | Dec 3, 2018 | Dr. D. Y. Patil Dental College & Hospital |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bold Therapeutics, Inc. | For profit | 1 | 1 | 1 | 2020 |
| Dr. D. Y. Patil Dental College & Hospital | Academic/Hospital | 1 | 1 | 1 | 2018 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2025 |
3 organizations
Page 1 / 1